Strategic Plan Objective Detail
Interagency Autism Coordinating Committee (IACC) logo
Office of Autism Research Coordination (OARC) logo

Question 1: Short-term Objective E  

$2,180,042.00
Fiscal Year: 2010

New! Green dot: Objective has greater than or equal to the recommended funding.1SE. Conduct at least one study to determine the positive predictive value and clinical utility (e.g., prediction of co-occurring conditions, family planning) of chromosomal microarray genetic testing for detecting genetic diagnoses for ASD in a clinical setting by 2012. IACC Recommended Budget: $9,600,000 over 5 years.

Download 2010 Question 1: Short-term Objective E projects (EXCEL)
Note: Initial Sort is by Principal Investigator. Sorting by other columns is available by clicking on the desired column header.
Project Title Principal Investigator Institution
Gene dosage imbalance in neurodevelopmental disorders Ledbetter, David Emory University
Clinical and gene signatures of ASDs Lewis, Suzanne University of British Columbia
Genomic identification of autism loci Eichler, Evan University of Washington

Objective Cumulative Funding Table

IACC Strategic Plan Objective 2008 2009 2010 2011 2012 Total
Conduct at least one study to determine the positive predictive value and clinical utility (e.g., prediction of co-occurring conditions, family planning) of chromosomal microarray genetic testing for detecting genetic diagnoses for ASD in a clinical setting by 2012.

IACC Recommended Budget: $9,600,000 over 5 years
N/A

N/A

1.S.E
$2,180,042
3 projects

1.S.E
$690,019
1 project

1.S.E
$1,273,122
4 projects

$4,143,183
1.S.E. Funding: The recommended budget for this objective was partially met.

Progress: Microarray testing is now recommended in AAP guidelines. The utility of this testing is more clear in cases where there is already a concern than for diagnostic use in the general population.

Remaining Gaps, Needs, and Opportunities: There is a need to better understand the relationship of genotype to phenotype, implications of genotype for treatment or medical management options, and to understand the potential impact of microarray testing on providers and families.